Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Page 1
Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design.
Gross R, Thaweethai T, Rosenzweig EB, Chan J, Chibnik LB, Cicek MS, Elliott AJ, Flaherman VJ, Foulkes AS, Witvliet MG, Gallagher R, Gennaro ML, Jernigan TL, Karlson EW, Katz SD, Kinser PA, Kleinman LC, Lamendola-Essel MF, Milner JD, Mohandas S, Mudumbi PC, Newburger JW, Rhee KE, Salisbury AL, Snowden JN, Stein CR, Stockwell MS, Tantisira KG, Thomason ME, Truong DT, Warburton D, Wood JC, Ahmed S, Akerlundh A, Alshawabkeh AN, Anderson BR, Aschner JL, Atz AM, Aupperle RL, Baker FC, Balaraman V, Banerjee D, Barch DM, Baskin-Sommers A, Bhuiyan S, Bind MC, Bogie AL, Buchbinder NC, Bueler E, Bükülmez H, Casey BJ, Chang L, Clark DB, Clifton RG, Clouser KN, Cottrell L, Cowan K, D'Sa V, Dapretto M, Dasgupta S, Dehority W, Dummer KB, Elias MD, Esquenazi-Karonika S, Evans DN, Faustino EVS, Fiks AG, Forsha D, Foxe JJ, Friedman NP, Fry G, Gaur S, Gee DG, Gray KM, Harahsheh AS, Heath AC, Heitzeg MM, Hester CM, Hill S, Hobart-Porter L, Hong TKF, Horowitz CR, Hsia DS, Huentelman M, Hummel KD, Iacono WG, Irby K, Jacobus J, Jacoby VL, Jone PN, Kaelber DC, Kasmarcak TJ, Kluko MJ, Kosut JS, Laird AR, Landeo-Gutierrez J, Lang SM, Larson CL, Lim PPC, Lisdahl KM, McCrindle BW, McCulloh RJ, Mendelsohn AL,… See abstract for full author list ➔ Gross R, et al. Among authors: schechter ms. medRxiv [Preprint]. 2023 May 12:2023.04.27.23289228. doi: 10.1101/2023.04.27.23289228. medRxiv. 2023. PMID: 37214806 Free PMC article. Updated. Preprint.
IMPORTANCE: The prevalence, pathophysiology, and long-term outcomes of COVID-19 (post-acute sequelae of SARS-CoV-2 [PASC] or "Long COVID") in children and young adults remain unknown. ...CONCLUSIONS AND RELEVANCE: RECOVER-Pediatrics seeks to characterize the clinical cours …
IMPORTANCE: The prevalence, pathophysiology, and long-term outcomes of COVID-19 (post-acute sequelae of SARS-CoV-2 [PASC] or "Long CO …
Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical Interpretations.
Szczesniak R, Andrinopoulou ER, Su W, Afonso PM, Burgel PR, Cromwell E, Gecili E, Ghulam E, Goss CH, Mayer-Hamblett N, Keogh RH, Liou TG, Marshall B, Morgan WJ, Ostrenga JS, Pasta DJ, Stanojevic S, Wainwright C, Zhou GC, Fernandez G, Fink AK, Schechter MS. Szczesniak R, et al. Among authors: schechter ms. Ann Am Thorac Soc. 2023 Jul;20(7):958-968. doi: 10.1513/AnnalsATS.202209-829OC. Ann Am Thorac Soc. 2023. PMID: 36884219
Marginal models consistently estimated less rapid lung function decline than mixed-effects models across scenarios, except for short-term follow-up (both were 1.4). Rate of decline estimates from nonlinear models diverged by age 30. ...Conclusions: Differences were as high …
Marginal models consistently estimated less rapid lung function decline than mixed-effects models across scenarios, except for short-term …
Reevaluating approaches to cystic fibrosis pulmonary exacerbations.
Schechter MS. Schechter MS. Pediatr Pulmonol. 2018 Nov;53(S3):S51-S63. doi: 10.1002/ppul.24125. Epub 2018 Jul 6. Pediatr Pulmonol. 2018. PMID: 29979495 Review.
Cystic Fibrosis (CF) lung disease is characterized by intermittent acute episodes of worsening signs, symptoms, and pulmonary function; these so-called pulmonary exacerbations (PEx) appear to be important drivers of long-term declines in lung function, quality of life, and …
Cystic Fibrosis (CF) lung disease is characterized by intermittent acute episodes of worsening signs, symptoms, and pulmonary function; thes …
Clinical Tools to Assess Asthma Control in Children.
Dinakar C, Chipps BE; SECTION ON ALLERGY AND IMMUNOLOGY; SECTION ON PEDIATRIC PULMONOLOGY AND SLEEP MEDICINE. Dinakar C, et al. Pediatrics. 2017 Jan;139(1):e20163438. doi: 10.1542/peds.2016-3438. Pediatrics. 2017. PMID: 28025241 Review.
Currently available ambulatory tools to measure asthma control range are subjective measures, such as patient-reported composite asthma control score instruments or objective measures of lung function, airway hyperreactivity, and biomarkers. Because asthma control exhibits short- …
Currently available ambulatory tools to measure asthma control range are subjective measures, such as patient-reported composite asthma cont …
Risk factors for quantity not sufficient sweat collection in infants 3 months or younger.
Collins MN, Brawley CB, McCracken CE, Shankar PR, Schechter MS, Rogers BB. Collins MN, et al. Among authors: schechter ms. Am J Clin Pathol. 2014 Jul;142(1):72-5. doi: 10.1309/AJCPLHG2BUVBT5LY. Am J Clin Pathol. 2014. PMID: 24926088
OBJECTIVES: The purpose is to identify demographic characteristics associated with a quantity not sufficient (QNS) sweat collection in infants 3 months or younger. METHODS: History of premature birth, infant race and sex, gestational age at delivery, and weight of the infa …
OBJECTIVES: The purpose is to identify demographic characteristics associated with a quantity not sufficient (QNS) sweat collection in infan …
Improving inpatient cystic fibrosis pulmonary exacerbation care: two success stories.
Antos NJ, Quintero DR, Walsh-Kelly CM, Noe JE, Schechter MS. Antos NJ, et al. Among authors: schechter ms. BMJ Qual Saf. 2014 Apr;23 Suppl 1:i33-i41. doi: 10.1136/bmjqs-2013-002367. BMJ Qual Saf. 2014. PMID: 24608549
BACKGROUND: Pulmonary exacerbations (PEx) in cystic fibrosis (CF) are a frequent cause of hospitalisations and lead to long-term decline in pulmonary function. Successful CF inpatient care requires the coordination of multiple providers and complex therapies. ...
BACKGROUND: Pulmonary exacerbations (PEx) in cystic fibrosis (CF) are a frequent cause of hospitalisations and lead to long-term decl …
Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis.
Schechter MS, Quittner AL, Konstan MW, Millar SJ, Pasta DJ, McMullen A; Scientific Advisory Group; Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis. Schechter MS, et al. Ann Am Thorac Soc. 2013 Jun;10(3):213-9. doi: 10.1513/AnnalsATS.201211-108OC. Ann Am Thorac Soc. 2013. PMID: 23802817
RATIONALE: Studies of pregnancy in cystic fibrosis (CF) have shown no short-term harmful effects, but there are no long-term studies on the impact of motherhood. OBJECTIVES: This study sought to evaluate longer-term physiologic and functional outcomes in wome …
RATIONALE: Studies of pregnancy in cystic fibrosis (CF) have shown no short-term harmful effects, but there are no long-term s …
Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms.
Regelmann WE, Schechter MS, Wagener JS, Morgan WJ, Pasta DJ, Elkin EP, Konstan MW; Investigators of the Epidemiologic Study of Cystic Fibrosis. Regelmann WE, et al. Among authors: schechter ms. Pediatr Pulmonol. 2013 Jul;48(7):649-57. doi: 10.1002/ppul.22658. Epub 2012 Sep 4. Pediatr Pulmonol. 2013. PMID: 22949088 Free PMC article.
The presence of these four characteristic signs and symptoms is useful to define pulmonary exacerbations in young children with CF that respond to antibiotic treatment in the short-term and influence long-term prognosis....
The presence of these four characteristic signs and symptoms is useful to define pulmonary exacerbations in young children with CF that resp …
Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial.
Robinson P, Schechter MS, Sly PD, Winfield K, Smith J, Brennan S, Shinkai M, Henke MO, Rubin BK. Robinson P, et al. Among authors: schechter ms. Pediatr Pulmonol. 2012 Jun;47(6):551-7. doi: 10.1002/ppul.21613. Epub 2012 Jan 20. Pediatr Pulmonol. 2012. PMID: 22266895 Clinical Trial.
In vitro and clinical data suggests that clarithromycin has immunomodulatory properties similar to other 14-member macrolides, however two previously reported short term, open label trials of clairthromycin in small numbers of patients with CF failed to show significant be …
In vitro and clinical data suggests that clarithromycin has immunomodulatory properties similar to other 14-member macrolides, however two p …
13 results